NCT02164006View on ClinicalTrials.gov

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 11, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

TGR-1202 + brentuximab vedotin

TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin

Trial Locations (4)

34232

TG Therapeutics Investigational Trial Site, Sarasota

48201

TG Therapeutics Investigational Trial Site, Detroit

91010

TG Therapeutics Investigational Trial Site, Duarte

92093

TG Therapeutics Investigational Trial Site, San Diego

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT02164006 - Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | Biotech Hunter | Biotech Hunter